BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 32929377)

  • 21. SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.
    Cairns J; Ingle JN; Wickerham LD; Weinshilboum R; Liu M; Wang L
    PLoS Genet; 2017 Oct; 13(10):e1007031. PubMed ID: 28968398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation.
    Pinho FG; Frampton AE; Nunes J; Krell J; Alshaker H; Jacob J; Pellegrino L; Roca-Alonso L; de Giorgio A; Harding V; Waxman J; Stebbing J; Pchejetski D; Castellano L
    Cancer Res; 2013 Oct; 73(19):5936-48. PubMed ID: 23928990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
    Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
    J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
    Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells.
    Ko YM; Wu TY; Wu YC; Chang FR; Guh JY; Chuang LY
    J Ethnopharmacol; 2011 Oct; 137(3):1283-90. PubMed ID: 21840388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J; Lu M; Jin J; Lu X; Xu T; Jin S
    Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
    Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
    Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer.
    Kim YS; Park SJ; Lee YS; Kong HK; Park JH
    Oncotarget; 2016 Jul; 7(27):42261-42273. PubMed ID: 27304060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR
    Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
    Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
    Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.
    Zhao JJ; Lin J; Yang H; Kong W; He L; Ma X; Coppola D; Cheng JQ
    J Biol Chem; 2008 Nov; 283(45):31079-86. PubMed ID: 18790736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
    J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X; Zhang Z
    IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
    Zheng L; Meng X; Li X; Zhang Y; Li C; Xiang C; Xing Y; Xia Y; Xi T
    FASEB J; 2018 Feb; 32(2):588-600. PubMed ID: 28939591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression.
    Zhu L; Li XX; Shi L; Wu J; Qian JY; Xia TS; Zhou WB; Sun X; Zhou XJ; Wei JF; Ding Q
    Oncol Rep; 2019 Jan; 41(1):455-464. PubMed ID: 30542717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.